Sodium Lactate Infusion in GLUT1DS Patients

Epilepsy Clinical Trial

Official title: Effects of Sodium Lactate Infusion in Patients With Glucose Transporter 1 Deficiency Syndrome (GLUT1DS)

Status Completed

Clinical Trial Summary

This study investigates the effect of lactate infusion on epileptic discharges on EEG and seizure frequency in glucose transporter 1 deficiency syndrome (GLUT1DS) patients.

Clinical Trial Description

In glucose transporter 1 deficiency syndrome (GLUT1DS) cerebral glucose uptake from the systemic blood circulation is limited, because of deficient transport of glucose across the blood-brain barrier by the transporter protein (GLUT1). Classically patients present with developmental problems, movement disorders and severe epilepsy. There is no curative treatment for GLUT1DS, and anti-epileptic drugs usually have little to no effect. The ketogenic diet, providing ketones as an alternative energy substrate for the brain is an effective treatment option for the epilepsy and movement disorders in many GLUT1DS patients. Unfortunately, not in all GLUT1DS patients the ketogenic diet has a positive effect and other treatment options for these patients are very limited.

Traditionally, lactate is seen as a waste product of glycolysis during anaerobic conditions and a marker of ischemia. Interestingly, research has shown the beneficial side of lactate as an energy source for different organs. It seems that the brain can indeed use lactate as an alternative energy metabolite, besides glucose and ketones. The aim of this study is to investigate whether lactate can be an alternative energy metabolite in the GLUT1DS brain, and reduce epileptic discharges on EEG when intravenously administered in patients with GLUT1DS. ;

Related Conditions & MeSH terms

• Epilepsy
• GLUT1 Deficiency Syndrome
• GLUT1DS1
• GLUT1DS2
• Hyperlactatemia
• Ketogenic Dieting
• Lactic Acid Blood Increased
• Syndrome

• NCT number: NCT04112862
• Study type: Interventional
• Source: Radboud University Medical Center
• Status: Completed
• Phase: Early Phase 1
• Start date: May 20, 2022
• Completion date: November 18, 2022